What is Gossamer Bio?
Headquartered in San Diego, California, Gossamer Bio operates at the intersection of biotechnology and clinical medicine. The company is dedicated to the discovery, acquisition, and development of transformative therapeutics. Its core focus areas include immunology, inflammation, and oncology—sectors that require significant capital intensity and long-term commitment to achieve regulatory success.
As a clinical-stage entity, Gossamer Bio distinguishes itself through a robust pipeline and a strategic focus on high-unmet-need patient populations. The company's business model relies on the efficient translation of biological insights into viable commercial assets, a process that necessitates both deep scientific expertise and sustained financial support from specialized life sciences investors.
How much funding has Gossamer Bio raised?
Gossamer Bio has raised a total of $357M across 2 funding rounds:
Share Placement
$120M
Share Placement
$212M
Share Placement (2022): $120M, investors not publicly disclosed
Share Placement (2023): $212M led by EcoR1 Capital, New Enterprise Associates, Armistice Capital, and Madison Avenue Partners
Key Investors in Gossamer Bio
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, aiming to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Armistice Capital
Armistice Capital is a global hedge fund that employs a long/short, value-oriented, and event-driven investment strategy, primarily targeting the health care and consumer sectors.
What's next for Gossamer Bio?
Looking ahead, the infusion of capital from this latest round will likely be directed toward the advancement of key clinical programs and the expansion of the company's therapeutic portfolio. As the firm navigates the complexities of late-stage development, the focus will remain on achieving critical data readouts that validate its proprietary platforms.
The strategic backing from institutional partners provides Gossamer Bio with the operational flexibility to pursue both internal innovation and potential external acquisitions. By maintaining a disciplined approach to resource allocation, the company aims to solidify its market position as a leader in the development of next-generation medicines, ultimately driving long-term value for stakeholders and improving patient outcomes in its target therapeutic areas.
